By Digifin Pty Ltd · About this coverage
Key Points
- Proposal published 18 November 2026 under the TCET pathway with Coverage with Evidence Development
- Would cover traditional Medicare and Medicare Advantage patients if finalised as proposed
- Covered patients to enrol in the proposed WiSE-CHOICE study for at least 24 months
- Public comments close 18 December 2026; final decision expected by 16 February 2027

About EBR Systems (ASX:EBR)
EBR Systems, Inc. is a medical device company headquartered in Santa Clara, California, with CHESS Depositary Interests listed on the ASX. It develops and sells the WiSE CRT System, a wireless pacing system for stimulating the left ventricle of the heart, in the United States.
EBR Systems (ASX:EBR) released this because the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed a National Coverage Determination for its WiSE System, a step towards national Medicare reimbursement.
The proposal was published on 18 November 2026 under CMS's Transitional Coverage for Emerging Technologies (TCET) pathway, with coverage under the Coverage with Evidence Development (CED) framework. If finalised as proposed, patients meeting the criteria would be covered through both traditional Medicare and Medicare Advantage plans. Currently, Medicare Advantage patients, whom the company puts at approximately 50% of the Medicare population, need case-by-case approval from regional Medicare Administrative Contractors. Consistent with the FDA-approved indication, proposed coverage includes previously untreatable patients whose coronary sinus lead implantation was unsuccessful or whose implanted lead has been turned off, and high-risk upgrades for patients with existing pacemakers or implantable cardioverter-defibrillators for whom a standard CRT upgrade is inadvisable. Covered patients would be enrolled in the proposed WiSE-CHOICE study, which compares real-world outcomes with standard treatments and tracks survival and heart failure hospitalisations over at least 24 months.
The proposal is not yet effective. Public comments close on 18 December 2026, with a final decision expected by 16 February 2027. The WiSE-CHOICE study is itself only proposed, and the release gives no estimate of revenue impact.
Source: EBR Systems, Inc. (ASX:EBR), 20 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.
